GAGE gene and protein expression profile in cancer patients

Cover Page

Cite item

Full Text

Abstract

Cancer-testis antigens (CTA) are antigens expressed by tumor cells of various histological types, but practically absent in cells of normal tissues, with the exception of germ cells. CTA includes more than 100 proteins, most of which are grouped into large families. Currently, the use of CTA for immunotherapy in the treatment of oncological diseases has been tested in many studies, and an increase in survival time has been achieved for many cases. Therefore, they can be promising targets for the creation of antitumor drugs, targeted therapy of tumors and as diagnostic biomarkers.

The purpose of this review was to study the GAGE family of antigens, one of the CTA groups recognized by T cells. Proteins of this family, expressed in tumor cells, stimulate the development of a humoral and cellular immune response against them. It follows from this that they fully meet the requirements for targets for tumor immunotherapy. The review provides information about the structure and sequence of genes encoding proteins of the GAGE family. The question of the role of GAGE in apoptosis is considered in detail and the results of studies proving that GAGE-7C makes cells resistant to apoptosis mediated by interferon γ or Fas are presented. The results of clinical studies of the expression of GAGE group genes and proteins in various types of tumor diseases are considered and examples of the reported correlation between GAGE expression and poor prognosis in some types of cancer are given.

Thus, the proteins of the GAGE group, with a detailed study, can become a possible diagnostic and prognostic marker of cancer diseases, and in the future be used to assess malignancy and monitor tumors for the selection of treatment tactics.

About the authors

A. A. Rudakova

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Author for correspondence.
Email: rudakovaan93@yandex.ru
ORCID iD: 0000-0001-7266-7689

Anna Andreevna Rudakova

24 Kashirskoe Shosse, Moscow 115478, Russia

Russian Federation

A. D. Shirin

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

ORCID iD: 0000-0003-3244-7774

24 Kashirskoe Shosse, Moscow 115478, Russia

Russian Federation

N. V. Golubtsova

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

ORCID iD: 0000-0002-8630-1968

24 Kashirskoe Shosse, Moscow 115478, Russia

Russian Federation

M. V. Pinyugina

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

ORCID iD: 0000-0003-0318-3896

24 Kashirskoe Shosse, Moscow 115478, Russia

Russian Federation

V. A. Misyurin

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

ORCID iD: 0000-0002-0762-5631

24 Kashirskoe Shosse, Moscow 115478, Russia

Russian Federation

References

  1. Stevenson B.J., Iseli C., Panji S. et al. Rapid evolution of cancer/testis genes on the X chromosome. BMC Genomics 2007;8:129. doi: 10.1186/1471-2164-8-129
  2. Fijak M., Meinhardt A. The testis in immune privilege. Immunol Rev 2006;213:66–81. doi: 10.1111/j.1600-065X.2006.00438.x
  3. Simpson A.J., Caballero O.L., Jungbluth A. et al. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005; (8):615–25. doi: 10.1038/nrc1669
  4. Head J.R., Billingham R.E. Immune privilege in the testis. II. Evaluation of potential local factors. Transplantation 1985;40(3):269–75. doi: 10.1097/00007890-198509000-00010
  5. Hutter H., Dohr G. HLA expression on immature and mature human germ cells. J Reprod Immunol 1998;38(2):101–22. doi: 10.1016/s0165-0378(98)00032-1
  6. Kirkin A.F., Dzhandzhugazyan K.N., Zeuthen J. Cancer/testis antigens: structural and immunobiological properties. Cancer Invest 2002;20(2):222–36. doi: 10.1081/cnv-120001150
  7. Van Der Bruggen P., Zhang Y., Chaux P. et al. Tumor-specific shared antigenic peptides recognized by human T cells. Immunol Rev 2002;188(1):51–64. doi: 10.1034/j.1600-065x.2002.18806.x
  8. Kawabata R., Wada H., Isobe M. et al Antibody response against NY-ESO-1 in CHP-NY-ESO-1 vaccinated patients. Int J Cancer 2007;120(10):2178–84. doi: 10.1002/ijc.22583
  9. Uenaka A., Wada H., Isobe M. et al. T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein. Cancer Immun 2007;7:9.
  10. Odunsi K., Qian F., Matsuzaki J. et al. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc Natl Acad Sci U S A 2007;104(31):12837–42. doi: 10.1073/pnas.0703342104
  11. Thurner B., Haendle I., Röder C. et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999;190(31):1669–78. doi: 10.1084/jem.190.11.1669
  12. Marchand M., van Baren N., Weynants P. et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 1999;80(2):219–30. doi: 10.1002/(sici)1097-0215(19990118)80:2<219::aidijc10>3.0.co;2-s
  13. Jäger E., Karbach J., Gnjatic S. et al. Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. Proc Natl Acad Sci U S A 2006;103(39):14453–8. doi: 10.1073/pnas.0606512103
  14. Davis I.D., Chen W., Jackson H. et al. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci U S A 2004;101(29):10697–702. doi: 10.1073/pnas.0403572101
  15. Burgdorf S.K., Fischer A., Claesson M.H. et al. Vaccination with melanoma lysate-pulsed dendritic cells, of patients with advanced colorectal carcinoma: report from a phase I study. J Exp Clin Cancer Res 2006;25(2):201–6.
  16. Reynolds S.R., Celis E., Sette A. et al. HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccinetreated melanoma patients. J Immunol 1998;161(12):6970–6.
  17. Reynolds S.R., Celis E., Sette A. et al. Identification of HLA-A*03, A*11 and B*07-restricted melanoma-associated peptides that are immunogenic in vivo by vaccine-induced immune response (VIIR) analysis. J Immunol Methods 2000;244(1–2):59–67. doi: 10.1016/s0022-1759(00)00254-4
  18. Van den Eynde B., Peeters O., De Backer O. et al. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J Exp Med 1995;182(3):689–98. doi: 10.1084/jem.182.3.689
  19. Traversari C., van der Bruggen P., Van den Eynde B. et al. Transfection and expression of a gene coding for a human melanoma antigen recognized by autologous cytolytic T lymphocytes. Immunogenetics 1992;35(3):145–52. doi: 10.1007/BF00185107
  20. Gjerstorff M.F., Ditzel H.J. An overview of the GAGE cancer/testis antigen family with the inclusion of newly identified members. Tissue Antigens 2008;71(3):187–92. doi: 10.1111/j.1399-0039.2007.00997.x
  21. Cilensek Z.M., Yehiely F., Kular R.K., Deiss L.P. A member of the GAFE family of tumor antigens is anti-apoptotic gene that confers resistance to Fas/CD95/APO-1, interferon-gamma, taxol and gamma-irradiation. Cancer Biol Ther 2002;1(4):380–7.
  22. Wadle A., Kubuschok B., Imig J. et al. Serological immune response to cancer testis antigens in patients with pancreatic cancer. Int J Cancer 2006;119(1):117–25. doi: 10.1002/ijc.21744
  23. Jäättelä M. Escaping cell death: survival proteins in cancer. Exp Cell Res 1999;248(1):30–43. doi: 10.1006/excr.1999.4455
  24. Lampros M., Vlachos N., Voulgaris S., Alexiou G.A. The Role of Hsp27 in chemotherapy resistance. Biomedicines 2022;10(4):897. doi: 10.3390/biomedicines10040897
  25. Cao X., Hou J., An Q. et al. Towards the overcoming of anticancer drug resistance mediated by p53 mutations. Drug Resist Updat 2020;49:100671. doi: 10.1016/j.drup. 2019.100671
  26. Tuxhorn J.A., Ayala G.E., Smith M.J. et al. Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clin Cancer Res 2002;8(9):2912–23.
  27. Gjerstorff M.F., Johansen L.E., Nielsen O. et al. Restriction of GAGE protein expression to subpopulations of cancer cells is independent of genotype and may limit the use of GAGE proteins as targets for cancer immunotherapy. Br J Cancer 2006;94(12):1864–73. doi: 10.1038/sj.bjc.6603163
  28. De Backer O., Arden K.C., Boretti M. et al. Characterization of the GAGE genes that are expressed in various human cancers and in normal testis. Cancer Res 1999;59(13):3157–65.
  29. Ruschenburg I., Kubitz A., Schlott T. et al. MAGE-1, GAGE-1/-2 gene expression in FNAB of classic variant of papillary thyroid carcinoma and papillary hyperplasia in nodular goiter. Int J Mol Medicine 1999;4(4):445–8. doi: 10.3892/ijmm.4.4.445
  30. Mischo A., Kubuschok B., Ertan K. et al. Prospective study on the expression of cancer testis genes and antibody responses in 100 consecutive patients with primary breast cancer. Int J Cancer 2006;118(3):696–703. doi: 10.1002/ijc.21352
  31. Kobayashi Y., Higashi T., Nouso K. et al. Expression of MAGE, GAGE and BAGE genes in human liver diseases: utility as molecular markers for hepatocellular carcinoma. J Hepatol 2000;32(4):612–7. doi: 10.1016/s0168-8278(00)80223-8
  32. Gillespie A.M., Rodgers S., Wilson A.P. et al. MAGE, BAGE and GAGE: tumour antigen expression in benign and malignant ovarian tissue. Br J Cancer 1998;78(6):816–21. doi: 10.1038/bjc.1998.585
  33. Bazhin A.V., Wiedemann N., Schnölzer M. et al. Expression of GAGE family proteins in malignant melanoma. Cancer Lett 2007;251(2):258–67. doi: 10.1016/j.canlet.2006.11.022
  34. Gjerstorff M.F., Pøhl M., Olsen K.E., Ditzel H.J. Analysis of GAGE, NY-ESO-1 and SP17 cancer/testis antigen expression in early stage non-small cell lung carcinoma. BMC Cancer 2013;13:466. doi: 10.1186/1471-2407-13-466
  35. Chen Y.T., Panarelli N.C., Piotti K.C., Yantiss R.K. Cancer-testis antigen expression in digestive tract carcinomas: frequent expression in esophageal squamous cell carcinoma and its precursor lesions. Cancer Immunol Res 2014;2(5):480–6. doi: 10.1158/2326-6066.CIR-13-0124
  36. Melo D.H., Mamede R.C.M., Neder L. et al. Expression of cancer/testis antigens MAGE-A, MAGE-C1, GAGE and CTAG1B in benign and malignant thyroid diseases. Oncol Lett 2017;14(6):6485–96. doi: 10.3892/ol.2017.7072
  37. Andrade V.C.C., Vettore A.L., Felix R.S. et al. Prognostic impact of cancer/testis antigen expression in advanced stage multiple myeloma patients. Cancer Immun 2008;8:2.
  38. Van Duin M., Broyl A., de Knegt Y. et al. Cancer testis antigens in newly diagnosed and relapse multiple myeloma: prognostic markers and potential targets for immunotherapy. Haematologica 2011;96(11):1662–9. doi: 10.3324/haematol.2010.037978
  39. Moreaux J., Klein B., Bataille R. A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines. Haematologica 2011;96(4):574–82. doi: 10.3324/haematol.2010.033456
  40. Ghafouri-Fard S., Seifi-Alan M., Shamsi R. et al. Immunotherapy in multiple myeloma using cancer-testis antigens. Iran J Cancer Prev 2015;8(5):e3755. doi: 10.17795/ijcp-3755
  41. Kubuschok B., Xie X., Jesnowsk R. et al. Expression of cancer testis antigens in pancreatic carcinoma cell lines, pancreatic adenocarcinoma and chronic pancreatitis. Int J Cancer 2004;109(4):568–75. doi: 10.1002/ijc.20006
  42. Ghadban T., Perez D.R., Vashist Y.K. et al. Expression of cancer testis antigens CT10 (MAGE-C2) and GAGE in gastrointestinal stromal tumors. Eur J Surg Oncol 2014;40(10):1307–12. doi: 10.1016/j.ejso.2014.03.011
  43. Oba-Shinjo S.M., Caballero O.L., Jungbluth A.A. et al. Cancertestis (CT) antigen expression in medulloblastoma. Cancer Immun 2008;8:7.
  44. Riener M., Wild P.J., Soll C. et al. Frequent expression of the novel cancer testis antigen MAGE-C2/CT-10 in hepatocellular carcinoma. Int J Cancer 2009;124(2):352–7. doi: 10.1002/ijc.23966
  45. Balafoutas D., Hausen A., Mayer S. et al. Cancer testis antigens and NY-BR-1 expression in primary breast cancer: prognostic and therapeutic implications. BMC Cancer 2013;13:271. doi: 10.1186/1471-2407-13-271
  46. Sharma P., Shen Y., Wen S. et al. Cancer-testis antigens: expression and correlation with survival in human urothelial carcinoma. Clin Cancer Res 2006;12(18):5442–7. doi: 10.1158/1078-0432.CCR-06-0527
  47. Sigalotti L., Coral S., Altomonte M. et al. Cancer testis antigens expression in mesothelioma: role of DNA methylation and bioimmunotherapeutic implications. Br J Cancer 2002;86(6):979–82. doi: 10.1038/sj.bjc.6600174
  48. Chen Y., Chiu R., Lee P. et al. Chromosome X-encoded cancer/testis antigens show distinctive expression patterns in developing gonads and in testicular seminoma. Hum Reprod 201;26(12):3232–43. doi: 10.1093/humrep/der33018
  49. Danilova A., Misyurin V., Novik A. et al. Cancer/testis antigens expression during cultivation of melanoma and soft tissue sarcoma cells. Clin Sarcoma Res 2020;10:3. doi: 10.1186/s13569-020-0125-2
  50. Cuffel C., Rivals J., Zaugg Y. et al. Pattern and clinical significance of cancer-testis gene expression in head and neck squamous cell carcinoma. Int J Cancer 2011;128(11):2625–34. doi: 10.1002/ijc.25607
  51. Zambon A., Mandruzzato S., Parent A. et al. MAGE, BAGE, and GAGE gene expression in patients with esophageal squamous cell carcinoma and adenocarcinoma of the gastric cardia. Cancer 2001;91(10):1882–8.
  52. Kong U., Koo J.Y., Choi K.H. et al. The expression of GAGE gene can predict aggressive biologic behavior of intestinal type of stomach cancer. Hepatogastroenterology 2004;51(59):1519–23.
  53. Cheung I.Y., Chi S.N., Cheung N.K. Prognostic significance of GAGE detection in bone marrows on survival of patients with metastatic neuroblastoma. Med Pediatr Oncol 2000;35(6): 632–634. doi: 10.1002/1096-911x(20001201)35:6<632::aidmpo31>3.0.co;2-1
  54. Gjerstorff M.F., Kock K., Nielsen O., Ditzel H.J. MAGE-A1, GAGE and NY-ESO-1 cancer/testis antigen expression during human gonadal development. Hum Reprod 2007;22(4):953–60. doi: 10.1093/humrep/del494
  55. D’Alessio A.C., Weaver I.C.G., Szyf M. Acetylation-induced transcription is required for active DNA demethylation in methylation-silenced genes. Mol Cell Biol 2007;27(21):7462–74. doi: 10.1128/MCB.01120-07
  56. Finashutina Yu.P., Misyurin V.A., Pushkova E.N., Misyurin A.V. Method of obtaining recombinant human GAGE1 protein. Patent for the invention RU 2652890С1, dated 05.03.2018.
  57. Mikhailova I.N., Kovalevsky D.A., Burova O.S. et al. Expression of cancer-testicular antigens in human melanoma cells. Sibirskiy oncologicheskiy zhurnal = Siberian Journal of Oncology 2010;1:29–39. (In Russ.).
  58. Mikhailova I.N., Kovalevsky D.A., Vishnevskaya Ya.V. et al. Expression of cancer-testicular antigen genes in primary human skin melanoma. Vestnik RONTS im. N.N. Blokhina RAMN = Journal of the N.N. Blokhin Russian Cancer Research Center 2010;21(2):52–65.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c)


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС77-53039 от  04.03.2013.